ACADIA Pharmaceuticals Return On Equity vs. Shares Owned By Insiders
| ACAD Stock | USD 16.29 0.08 0.49% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.14) | Current Value (0.15) | Quarterly Volatility 0.3497233 |
For ACADIA Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ACADIA Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ACADIA Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ACADIA Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ACADIA Pharmaceuticals over time as well as its relative position and ranking within its peers.
ACADIA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ACADIA Pharmaceuticals Shares Owned By Insiders vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ACADIA Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ACADIA Pharmaceuticals value to that of its competitors to determine the firm's financial worth. ACADIA Pharmaceuticals is number one stock in return on equity category among its peers. It is rated below average in shares owned by insiders category among its peers making about 1.97 of Shares Owned By Insiders per Return On Equity. At present, ACADIA Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value ACADIA Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ACADIA Shares Owned By Insiders vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
ACADIA Pharmaceuticals |
| = | 0.27 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
ACADIA Pharmaceuticals |
| = | 0.54 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
ACADIA Shares Owned By Insiders Comparison
ACADIA Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
ACADIA Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ACADIA Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ACADIA Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of ACADIA Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of ACADIA Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 24 K | 25.2 K | |
| Operating Income | -73.4 M | -77 M | |
| Net Loss | -61.3 M | -64.4 M | |
| Income Tax Expense | 10.2 M | 10.8 M | |
| Income Before Tax | -51 M | -53.6 M | |
| Total Other Income Expense Net | 22.3 M | 23.5 M | |
| Net Loss | -194.4 M | -204.1 M | |
| Net Loss | -61.3 M | -64.4 M | |
| Non Operating Income Net Other | -2.1 M | -2 M | |
| Interest Income | 17.2 M | 18.1 M | |
| Net Interest Income | 17.2 M | 18.1 M | |
| Change To Netincome | 71.2 M | 56.3 M | |
| Net Loss | (0.37) | (0.39) | |
| Income Quality | (0.27) | (0.26) | |
| Net Income Per E B T | 1.20 | 0.82 |
ACADIA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ACADIA Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ACADIA Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ACADIA Pharmaceuticals' important profitability drivers and their relationship over time.
Use ACADIA Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACADIA Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACADIA Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.ACADIA Pharmaceuticals Pair Trading
ACADIA Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to ACADIA Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACADIA Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACADIA Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACADIA Pharmaceuticals to buy it.
The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACADIA Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACADIA Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACADIA Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ACADIA Pharmaceuticals position
In addition to having ACADIA Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
To fully project ACADIA Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ACADIA Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ACADIA Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.